Gerard M. Housey, M.D., Ph.D.
Dr. Housey is the President and CEO of Housey Pharmaceutical Research Laboratories, and directs the company's research and development programs. Dr. Housey is the inventor of target-specific cell-based assay systems, a core, enabling technology that is currently in widespread use within the pharmaceutical industry.
Dr. Housey received his undergraduate degree from the University of Michigan, and his Ph.D. in Human Genetics (1988) and M.D. (1991) from Columbia University’s College of Physicians and Surgeons in New York City. He is a licensed physician in New York and Michigan. During his graduate studies he filed his first patent applications in the area of cell-based assay technology and founded Progenics Pharmaceuticals, Inc., (Nasdaq: PGNX) in 1986. He served as president of that company from inception until 1990. From 1991 to 1993 he was a resident physician in Clinical Pathology and Laboratory Medicine in the Department of Pathology at Columbia University's Presbyterian Hospital in New York. From 1994-1995 he conducted cancer research as a basic science fellow at the National Cancer Institute (National Institutes of Health) in Frederick, Maryland.
Thomas klema, cpa, Mba
Mr. Klema is the Chief Financial Officer of Housey Pharma and related companies including Housey Healthcare, Inc. Mr. Klema is responsible for the accounting, finance, business development, and other administrative activities of the Housey entities. Mr. Klema was Chief Financial Officer and Corporate Secretary of a publicly traded life science company, Rockwell Medical, Inc. for 19 years and was involved in FDA approval of three new drug applications and one abbreviated new drug application. He was a Vice President and held a variety of management and leadership roles at chemical specialty leader Diversey Lever for 17 years.
He received his MBA in Finance & a Bachelor of Arts in Accounting from Michigan State University. He achieved the CPA designation, and has audit experience at a national accounting firm.
edward bastyr iii, M.d.
Dr. Bastyr serves as the Chief Medical Officer of Housey Healthcare, Inc. (HHI). He is Board Certified in Internal Medicine and Endocrinology Diabetes and Metabolism by the American Board of Internal Medicine.
Prior to joining HHI, Dr. Bastyr served as Vice President Medical of MB2 LLC, a small biopharma company engaged in the development of peptides with specific binding to glucagon inhibitory peptide (GIP), glucagon like peptide -1 (GLP-1 ) and glucagon (GCG) for the treatment of diabetes. During his tenure at MB2 he led the clinical development of two new molecular entities for the treatment of diabetes, resulting in the successful sale and transfer of these compounds to Novo Nordisk.
Before serving as Vice President Medical of MB2, Dr. Bastyr spent nearly 20 years at Lilly Research Laboratories (LRL), Eli Lilly & Co. (“Lilly”; Indianapolis, IN). He held various positions in drug development in LRL and was involved in the design and implementation of numerous clinical trials utilizing innovative methods and creative concepts for the treatment of diabetes and its complications, including the successful registration of dulaglutide (Trulicity®) based upon the clinical plan developed and negotiated with regulatory agencies in the United States and Europe. His work at Lilly was recognized with the President’s Recognition Award for Outstanding Scientific Achievement (Top 1% Scientist Award) in 2002, 2009 and 2014.
Dr. Bastyr received his Baccalaureate degree in Biochemistry from Columbia College, Columbia University, a Master of Science degree in Biochemistry from the University of Chicago and his M.D. degree from Universidad De Navarra in Spain. He trained in Internal Medicine at the University of Pittsburgh Mercy Hospital and Endocrinology at the University of Michigan Medical Center prior to his appointment to faculty positions at the University of Texas Medical Branch and Indiana University School of Medicine. He has published more than 150 abstracts and manuscripts in diabetes peer reviewed publications.
timothy R. franson, M.d.
Dr. Franson serves as Global Regulatory Affairs consulting expert for Housey Pharma and its subsidiary, Housey Healthcare, Inc. (HHI). He advises on regulatory strategy and guidance for the Phase 2 Human Clinical Trials program for HP-211, Housey Pharma’s first-in-class, botanical anti-diabetic medicine. Dr. Franson is a Principal at Faegre Drinker Consulting, a subsidiary of Faegre Drinker Biddle, where he leads their regulatory affairs practice.
Dr. Franson was formerly the Vice President of Global Regulatory Affairs at Eli Lilly & Company, one of the largest diabetes-focused pharmaceutical companies in the world. Dr. Franson held increasing responsible positions at Eli Lilly from 1986 until 2008, including VP of Clinical Research and Regulatory Affairs-US from 1997 to 2003 and VP of Global Regulatory Affairs, a position he held for five years at Eli Lilly from 2003 through 2008.
Dr. Franson has authored more than 50 articles in the fields of infectious disease, epidemiology, pharmacoeconomics, and antibiotic utilization. He holds a B.S. in pharmacy from Drake University and an M.D. from the University of Illinois College of Medicine. He is board certified in Internal Medicine and Infectious Diseases, and Adjunct Professor of Medicine at Indiana University School of Medicine. Click here for a complete listing of his biography.
Business Advisory Board
Mr. Hosier is a nationally recognized attorney specializing in business and intellectual property law. Mr. Hosier obtained a Bachelor of Science in Electrical Engineering from Northwestern University in 1963 and a Juris Doctorate in Law from DePaul University in 1967. He is admitted before various United States District Courts, United States Courts of Appeal, and the United States Supreme Court. He has been actively engaged in the practice of law from 1967 through the present.
Mr. Hosier’s legal practice embraces various aspects of business law including intellectual property, antitrust and unfair competition law. He has been recognized as a leader in the US legal profession by various publications including the American Lawyer, Forbes, and Fortune magazines.
Mr. Hosier has long been an active venture capital investor. He has served as a founding investor and/or board member for businesses in diverse technical fields including electronic video games, electronic voting machines, massively parallel super computers, applied proteomics, and biopharmaceutical R&D. He and his two sons are currently the managing partners of Brush Creek Capital, a family investment company.
Mr. Hosier has established a family foundation to support many charitable causes. Among other things, he was an anchor donor for the Aspen Center for Physics and the Doerr-Hosier Center at the Aspen Institute. In 2000, he established a Distinguished Visiting Professorship at DePaul University Law School.
Business Advisory Board
Frank Migliazzo began his Merrill Lynch career in 1979. As the leader of The Migliazzo Group, Frank provides strategic direction and investment policy for the team. Over the course of his career, he has witnessed a number of market cycles and economic conditions. He applies his knowledge, experience, and judgment in crafting investment portfolios that anticipate and respond to varied market environments.
Frank is one of approximately eighty advisors nationally who are designated as Global Institutional Consultants at Merrill Lynch. Frank has served as Chair of two prestigious leadership bodies within the Firm: the National Advisory Council to Management at Merrill Lynch and the Private Banking and Investment Group Advisory Council to Management. Barron’s Magazine has named Frank one of the Top 1,000 Advisors in America, from the inception of the accolade in 2009 through 2013 inclusively.
He earned his undergraduate degree from Western Michigan University and his M.B.A. from the University of Detroit. He is a CERTIFIED FINANCIAL PLANNER™ certificant, a designation awarded by the Certified Financial Planner Board of Standards, Inc. Frank also holds the Certified Investment Management Analyst® (CIMA®) designation sponsored by the Investment Management Consultants Association (IMCA) at the Wharton School.
Scientific Advisory Board Cancer
Dr. Sawyers is the Marie-Josee and Henry R. Kravis Chair and Director of Human Oncology and Pathogenesis at the Memorial Sloan-Kettering Cancer Center in New York. He is also an Investigator in the Howard Hughes Medical Institute. Dr. Sawyers is well-known in leukemia circles for his work on the BCR-ABL tyrosine kinase in chronic myelogenous leukemia. He was a primary participant in the design and conduct of clinical trials of the ABL tyrosine kinase inhibitor STI571 (Gleevec), and his lab was the first to identify mechanisms of drug resistance due to Bcr-Abl gene mutation and amplification. He has also applied his expertise in signal transduction to human prostate cancer. His group has developed a novel set of human prostate cancer xenografts which have allowed molecular biological investigations into the mechanisms of hormone-refractory prostate cancer progression and metastasis. Most recently, his laboratory has implicated deregulation of the PTEN/AKT pathway as a major event in advanced prostate cancer.
Dr. Sawyers received his undergraduate degree from Princeton University and his medical degree from the Johns Hopkins School of Medicine. He completed a residency in Internal Medicine at the UCSF Medical Center, and a clinical fellowship in Hematology/Oncology at the UCLA School of Medicine. He also completed a post-doctoral fellowship in Molecular Biology at the UCLA School of Medicine. Dr. Sawyers is board certified in internal medicine, medical oncology, and hematology. He has published over 70 scientific and medical papers in such journals as the New England Journal of Medicine, Science and Cell. Dr. Sawyers has won numerous honors and awards, including the Franklin D. Murphy Prize, Stohlman Scholar of the Leukemia and Lymphoma Society, Doris Duke Distinguished Clinical Scientist Award, and was the Peter Bing Professor at the UCLA School of Medicine. Beginning fall of 2002, Dr. Sawyers became an Investigator of the Howard Hughes Medical Institute. In 2009, Dr. Sawyers received the Lasker Award, one of the most prestigious honors in science, for his work elucidating the underlying causes of drug-resistant chronic myelogenous leukemia (CML). These findings led to the development of novel treatments for the disease.
Business Advisory Board
Doug Walter specializes in corporate and investment structuring and tax law. He obtained a Bachelor of Arts degree from Harvard University in 1966 and a Juris Doctorate degree in law from the Harvard Law School. He also attended London School of Economics in 1967 where he was an Officer of Law Review.
From 1967 to 1988 he was an associate, then a partner, at Bell, Boyd & Lloyd in Chicago. He then became a partner at Jones Day in Chicago from 1988 to 1999, and later a Consultant in 2000 and 2001.
He has been a member of the University of Chicago Tax Conference Planning Committee for many years and frequently speaks at its tax conference. Doug has also written numerous articles in the area of tax law and corporate structuring.
Mr. Walter has been Member of the University of Chicago Tax Conference Planning Committee for many years and a frequent speaker at its annual Tax Conference. Together with his wife, Pam Walter, Doug has been involved with numerous charitable activities. These include serving on the Steering Committee of Founders’ Council; Field Museum of Natural History; Former co-President of Founders’ Council and ex-officio member of Board of Field Museum. He is also an avid supporter of the Chicago Shakespeare Theater and the Illinois Institute of Technology.
Doug is a renaissance man, with interests ranging from corporate structuring, international tax planning, and olive farming to high technology and biomedical research innovation. His decades of experience brings a wealth of value to the Housey Group as the companies seek to expand their technology development and health care products and technologies to markets around the world.
Scientific Advisory Board Diabetes
Dr. White is a Professor of Pediatrics at Children's Hospital of Boston, Harvard Medical School, and an Investigator in the Howard Hughes Medical Institute. Dr. White and his colleagues were the first to identify the insulin receptor substrate (IRS) family of proteins, a key protein family that mediates the downstream signaling pathways initiated by the binding of Insulin to the insulin receptor. His findings suggest major new mechanisms for the treatment of diabetes, especially type II diabetes, a disease which is reaching epidemic proportions in the developed world. Furthermore, since diabetes is a complicated, multi-system disease, Dr. White's award-winning studies also may shed new light on certain metabolic and other disorders, such as obesity and fertility, which have common or highly related signal transduction mechanisms.
Dr. White received both his undergraduate degree and his Ph.D. degree from the University of Michigan. He performed a research fellowship in Medicine at the Harvard Medical School, and was subsequently appointed Professor of Biochemistry in the Department of Medicine at Harvard. Dr. White has served on the editorial boards of several leading journals, including the Journal of Biological Chemistry, Diabetes, and Molecular Endocrinology. Dr. White is a former Pew Scholar, and also won numerous awards and honors in the field of diabetes research, most notably the Eli Lilly Award for Excellence in Scientific Achievement from the American Diabetes Association (1999), and the Excellence in Diabetes Research Award from the Juvenile Diabetes Foundation (1995).